TAMPA, Fla. (PRWEB) June 27, 2008
PanGenex has invested over $2.4M in research and development to successfully launch LIPIDEME™, an all-natural product that addresses high cholesterol, Omeganol™, the purest and most highly concentrated Omega-3 supplement available without a prescription and Calci-CLEAR™ to address soft-tissue calcification. These products are focused on assisting people worldwide in maintaining a healthy lifestyle. PanGenex sales have increased with the launch of the new websites and we are proud to have renowned cardiologists such as Director Ronald P. Caputo, MD, FACC, FSCAI to endorse LIPIDEME and Omeganol.
"We feel that we are perfectly positioned to play a major role in this $70B dollar industry due to the strength of our product formulations and the support of our physicians. We are currently in the process of establishing a clinical study on one of our products which we believe will have a major impact on the 64 million Americans that deal with cardiovascular disease. Additionally, we are finalizing plans for a national roll-out of a PanGenex developed proprietary product supported by a comprehensive market plan that will be as complete as any item previously introduced in the nutraceutical category," explained Jeff Roman, President and CEO of PanGenex. "We have already achieved a 'Current Information' classification through Pink Sheets and the world-class Board of Directors that is coming together teamed with our counsel and accountants will allow us to aggressively proceed towards the filing of a 15c2-11 and a move to the OTC Bulletin Board by this fall. PanGenex is actively working on securing the services of several firms to bring institutional investor dollars into the company. As CEO of PanGenex, I am committed to keep our shareholders abreast of all corporate information in an accurate and transparent manner."
Learn More about PanGenex Corporation at:
Visit HearthHealthyWorld.com at:
The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.